Alkermes

pharma

Dublin, · ALKS · Public

Alkermes is advancing its orexin agonist program (alixorexton) into Phase 3 development with positive Phase 2 data and orphan drug designations, while integrating the Avadel Pharmaceuticals acquisition to strengthen its sleep disorder portfolio. The company is executing on a growth thesis centered on hypersomnolence and narcolepsy treatments alongside its core psychiatric medication business.

Alkermes plc is an Irish-headquartered biopharmaceutical firm, established in 1987, focused on the discovery, development, and commercialization of innovative pharmaceutical treatments. These efforts are directed at fulfilling critical unmet medical needs for patients across a range of therapeutic areas, both domestically and internationally. Its current portfolio of marketed products features ARISTADA for schizophrenia; VIVITROL, targeting alcohol dependence and preventing opioid dependence; and several medications for schizophrenia and bipolar I disorder, including RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA. Furthermore, VUMERITY is available for managing relapsing forms of multiple sclerosis in adults, encompassing clinically isolated syndrome, relapsing-remitting, and active secondary progressive diseases. The company is also actively developing new drug candidates, such as LYBALVI, an oral atypical antipsychotic for adults with schizophrenia and bipolar I disorder, and nemvaleukin alfa, an engineered fusion protein designed to amplify tumor-killing immune cells while bypassing the activation of immunosuppressive cells. Alkermes maintains key strategic collaboration agreements, primarily with various entities under the Janssen Pharmaceutica umbrella.

Employees

1,800

Mfg Plants

All Facilities

Activity

7/10

Type

Public